Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 56Recurrence 16Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Leukemia, Myeloid, Acute 8Lymphoma, Follicular 7Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasms 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Sezary Syndrome 2Paraproteinemias 2Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2

Interventions

liposomal doxorubicin 1Melphalan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Patient Participation × Bortezomib × Clear all
NCT00985907 2020-06-17

DMV

University of California, San Francisco

Phase 1/2 Terminated
13 enrolled 8 charts
Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡